New immunotherapy approach holds promise for ovarian cancer
A new approach using CAR T-cell therapy is suggested by Swedish researchers as an effective treatment for ovarian cancer.
List view / Grid view
A new approach using CAR T-cell therapy is suggested by Swedish researchers as an effective treatment for ovarian cancer.
US scientists have outlined the structure and function of the first FDA approved drug for the Ebola virus.
US researchers found that serotonin impacts the mitral valve in the heart which can lead to heart valve disease.
A US pre-clinical study investigating the antidepressant: MAP4343, discovered it reduced alcohol intake in a mouse model of alcoholism.
Japanese researchers find a new mechanism for how the measles virus can cause a rare but fatal neurological disorder: subacute sclerosing panencephalitis (SSPE).
Streamline oncology therapeutic development with CST® recombinant monoclonal antibodies, ELISA & cellular assay kits, & custom products & services.
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
US researchers discovered a type of cell involved it pancreatic cancer and sheds light on the origin of cancer-associated fibroblasts (CAFs).
30 January 2023 | By Thermo Fisher Scientific
Watch this webinar to learn how an integrated structural biology workflow can be used to get crucial structural insights on key protein targets that are of therapeutic interest.
US researchers will use a unique combination of imaging techniques (MRI and MSI) to study Alzheimer’s disease on a scale that has never been done before.
US research about immunological memory may help development of potential vaccines or immunotherapies for cancer and various inflammatory diseases.
US researchers use new imaging technique to see cardiac reactions to noradrenaline, the ‘fight or flight’ hormone.
US researchers revealed that MRSA has undergone repeated mutations in the sarZ gene, leading to increased severity of blood stream infections in mouse models.
US researchers discover a potential therapeutic avenue through the molecule NgR2, against an aggressive form of prostate cancer.
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally.